Beyang Therapeutics has raised nearly $30 million in an oversubscribed Series A financing round as the drug discovery company moves to expand its proprietary ExCEED platform and advance its pipeline of potential treatments. The funding gives Beyang more resources to develop its technology and move key drug candidates through clinical and preclinical development.
The company announced the financing on August 12, 2026. The Series A round was co-led by Legend Capital and Shanghai Healthcare Capital, with participation from China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital and Harbor & Canton Capital. Existing investors Root Venture Partners and YuanBio Venture Capital also participated in the round.
Funding Will Support Drug Development
Beyang Therapeutics said it will use the new capital mainly to continue developing its ExCEED platform, advance key pipeline candidates through clinical and preclinical development, and expand its international research and business development teams.
The company describes ExCEED as its core platform for molecular design and optimization. It combines proprietary databases with artificial intelligence and computational simulation across areas such as molecular design, druggability optimization, and biological evaluation. Beyang was founded in 2021 and has built a team with more than two decades of experience in drug discovery and computational simulation, according to the company.
ExCEED Platform Advances Drug Discovery
Beyang is using ExCEED to identify and develop new drug candidates. The company says the platform can support the generation of new molecular structures rather than only modifying existing drug structures.
The platform also recently received recognition in the OpenADMET blind prediction challenge, where Beyang ranked eighth globally among more than 350 participants, according to the company. OpenADMET focuses on predicting drug-related properties through computational methods.
While the company highlights these results as evidence of the platform’s capabilities, the technology and drug candidates remain part of an ongoing research and development process. Clinical studies will ultimately determine whether the candidates can demonstrate safety and effectiveness in patients.
Ophthalmology Program Moves Toward Patient Testing
One of Beyang’s leading programs is BT01001, a small-molecule eye drop being developed for retinal diseases.
According to Beyang, preclinical head-to-head studies showed that BT01001 achieved strong exposure in ocular tissues, while its efficacy was comparable to intravitreal injections of aflibercept in those studies. The company also said the candidate completed Phase I single ascending dose and multiple ascending dose studies in healthy subjects, with favorable safety and tolerability results.
Beyang is now preparing to move BT01001 toward first-in-patient trials. The company aims to develop a non-invasive treatment option for diseases affecting the fundus of the eye. Importantly, these findings are based on preclinical and early-stage clinical development. They do not establish that BT01001 is already an effective treatment for patients.
Second-Generation Menin Inhibitor in Development
Beyang is also advancing BT01002, a second-generation Menin inhibitor being developed for acute leukemia associated with KMT2A rearrangements or NPM1 mutations.
The company designed BT01002 to address resistance mechanisms that can limit the effectiveness of first-generation Menin inhibitors. Beyang says the candidate’s molecular design is intended to overcome known resistance mechanisms. BT01002 is currently in IND-enabling studies, meaning Beyang is conducting the required preclinical work needed to support a potential Investigational New Drug application and future clinical testing.
Experienced Team Behind Beyang
Beyang said its core team includes scientists with experience at major pharmaceutical companies, including Pfizer, Merck and Hengrui. The team has participated in the development of three small-molecule drugs that have reached global markets and has advanced more than 10 projects into clinical trials, according to the company.
Founder Qiyue Hu said the oversubscribed financing reflects investor confidence in the company’s ExCEED platform and drug pipeline. Beyang also plans to pursue external collaborations as it works to develop new drug candidates for patients and partners worldwide.
Investors Back Beyang’s Next Phase
The participation of both new and existing investors gives Beyang additional capital to continue its development strategy. Legend Capital and Shanghai Healthcare Capital led the financing, while CMS, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital and Harbor & Canton Capital joined the round. Root Venture Partners and YuanBio Venture Capital also returned as existing investors.
For Beyang, the Series A funding marks an important step as it works to take its drug discovery platform and pipeline into later stages of development. The company will now focus on improving ExCEED, advancing BT01001 toward patient testing and continuing development of BT01002.
The funding does not guarantee clinical or regulatory success, but it gives Beyang the financial backing to continue testing its approach. The progress of its clinical programs and the data generated in future studies will be key to determining whether the company’s drug candidates can eventually become viable treatments.
